Genome wide association neural networks (GWANN) identify novel genes linked to family history of Alzheimer's disease in the UK Biobank

Upamanyu Ghose * [1, 2]   upamanyu.ghose@psych.ox.ac.uk

William Sproviero [1]   william.sproviero@psych.ox.ac.uk

Laura Winchester [1]   laura.winchester@psych.ox.ac.uk

Marco Fernandes [1]   marco.fernandes@psych.ox.ac.uk

Danielle Newby [3, 1]   danielle.newby@ndorms.ox.ac.uk

Brittany S. Ulm [2, 7]   brittany.ulm@ndph.ox.ac.uk

Liu Shi [1]   liu.shi@psych.ox.ac.uk

Qiang Liu [1]   qiang.liu@psych.ox.ac.uk

Cassandra Adams [2, 4]   cassandra.adams@cmd.ox.ac.uk

Ashwag Albukhari [2, 5]   aalbukhari@kau.edu.sa

Majid Almansouri [2, 6]   malmansouri@kau.edu.sa

Hani Choudhry [2, 7]   hchoudhry@kau.edu.sa

Cornelia van Duijn [2, 7, 8]   cornelia.vanduijn@ndph.ox.ac.uk

Alejo Nevado-Holgado [1, 2, 7]   alejo.nevado-holgado@psych.ox.ac.uk

[1] Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom.
[2] Centre for Artificial Intelligence in Precision Medicines.
[3] Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7HE, United Kingdom.
[4] Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom.
[5] Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
[6] Clinical Biochemistry Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
[7] Big Data Institute, University of Oxford, Oxford OX3 7LF, United Kingdom.
[8] Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
* Corresponding Author

1 Abstract

Augmenting traditional genome wide association studies (GWAS) with advanced machine

learning algorithms can allow the detection of novel signals in available cohorts by providing

complementary approaches to the existing methods. We introduce "Genome wide

association neural networks (GWANN)", a novel approach that uses neural networks (NNs)

to account for nonlinear and SNP-SNP interaction effects. We applied GWANN to family

history of Alzheimer's disease (AD) in the UK Biobank. Our method identified 26 known AD

genes, 2 target nominations and 67 novel genes, and validated the results against brain

eQTLs, AD phenotype associations, biological pathways, disease associations and

differentially expressed gene sets in the AD brain. Some drugs targeting novel GWANN hits

are currently in clinical trials for AD. Applying NNs for GWAS, alongside existing methods,

illustrates their potential to complement existing algorithms and methods, and enable the

discovery of novel and tractable targets for AD.

KEYWORDS: Alzheimer's disease, neural networks, artificial intelligence, GWAS

ABBREVIATIONS: NN - Neural Network; GWANN - Genome Wide Association Neural

Networks; UKB - UK Biobank; PPI - Protein-Protein Interaction; GSEA - Gene Set

Enrichment Analysis; ORA - Over Representation Analysis; CDF - Cumulative Distribution

Function; GO - Gene Ontology

1 Introduction

Alzheimer's disease (AD) affects approximately 30 million people in the world, making it the

most common form of dementia[1]. It is characterised by the build-up of Aβ and tau proteins in

the brain, leading to neuronal death and impaired cognitive function[2]. In the last 10 years,

genome wide association studies (GWAS) have revolutionised our understanding of the

inherited basis of disease and they have been critical in identifying multiple risk loci and

novel disease pathways associated with AD involving the microglia and lysosome[3].

However, the classical GWAS analysis depends on sample size, and despite the number of

SNPs identified until today, they still only explain a small fraction of the heritability of the

disease[4]. Although gene-based methods were developed to identify the joint effects of rare

variants[5], or gene-level analysis from GWAS summary data[6], there are currently no methods

to perform gene-based studies for common variants.

Along with the modern availability of large datasets[7–9], to complement and enhance current

GWAS methods, we propose to use an approach based on machine learning to shed light

on more complex patterns in genomic mechanisms involving gene interactions and non-

linear relationships. Machine learning methods, more particularly Neural Networks (NNs),

have been instrumental in the advancement of multiple engineering industries due to their

efficacy in analysing complex data patterns[10], especially where large amounts of data are

available. Compared to the success of classical GWAS, the successes of NN in gene

discovery has been limited. NNs have recently been employed and tested on various

complex traits and diseases including eye colour and schizophrenia[11]. Our aim was to

develop NNs specialised to perform a gene-level GWAS using SNP data available in the UK

Biobank (UKB)[12]. Our method is gene-based and considers groups of SNPs within and

around each gene in the genome to establish the association of the gene with the phenotype

of interest. In this paper we demonstrate the application of our new GWANN method as a

complementary method to existing GWAS methods, to identify associations with familial

history of Alzheimer's disease/dementia, a proxy that has been successfully used to identify

new genes for AD in the UKB[7]. We present the genetic associations to family history of AD

found by the method, and systematically validate the results against brain eQTLs, AD and

related phenotype associations, biological pathways, disease associations and differentially

expressed gene sets in the AD brain.

2 Results

2.1 Identification of novel genes related to AD using GWANN

We applied GWANN to 26,133 cases and controls of maternal history of AD, and 12,680 cases and controls of paternal history of AD. The analysis was run at a gene-level, where the SNPs within a gene and in the flanking 2500 bp region were mapped to the gene. Each gene was divided into windows containing a maximum of 50 SNPs, and a separate model (Figure 1) was trained for each window. In addition to the SNPs, age (field 21003), sex (field 31), the first six genetic principal components (PCs) obtained from UKB variables (field 22009), education qualification (field 6138), and a binary variable if this data was not available (1 if missing and 0 if not) were used as covariates.

GWANN identified 69 genes significantly associated with maternal history, 29 genes associated with paternal history, and 95 genes in the parental (i.e., maternal and paternal) meta-analysis (Figure 3, Supplementary Table 1), after multiple-comparison correction based on a Bonferroni threshold of P value<6.82×10^{-7} (Figure 2, Supplementary Table 2). Table 1 lists the genes with their P values. The flanking region of 2500 bp around each gene caused an overlap between windows of *GEMIN7* and *PPP1R37*, and *APOE* and *TOMM40*. However, there was no overlap between the significant windows in the first case, and in the second case, *TOMM40* had a significant non-overlapping window in addition to the significant window that overlapped with *APOE*. Additionally, for the significantly associated genes, we used the gradient of the inputs with respect to the loss function of the NNs to identify the top input features (SNPs or covariate encodings) which had the largest influence on the prediction of the NN. The top three features were among the SNPs within the windows of the hit genes in both, maternal and paternal history analyses, except *ARHGAP24, PITPNM2, UBE3A, CRISPLD1 and GEMIN7*, in the paternal history analysis, where the NNs gave more importance to some of the covariate encodings (Supplementary

Table 2). Apart from the *APOE* locus, significant gene windows in *LRP1B* and *PARD3B*;

CNTN4 and *ROBO1*; *STAC* and *CADM2*; *TYW1B, EPHA1-AS1* and *MAGI2*, were in linkage

disequilibrium (LD, $r^2 \geq 0.8$) with each other (Supplementary Table 3). The significant genes

were further than 500 kbp from each other, except for the *APOE* locus on chromosome 19,

and *PTPRN2* and *VIPR2* on chromosome 7 (440 kbp). Supplementary File 2 contains the

locus zoom plots for the GWANN hits, which show a neighbourhood of 500 kbp around the

hit genes.

A standard SNP-level GWAS performed using PLINK 2.0 with a logistic regression model,

on the same set of SNPs, covariates, and individuals as used in GWANN, identified 13

genes for maternal history, four genes for paternal history, and 14 genes in the meta-

analysis, all of which were in the *APOE* locus, and previously identified in the UKB[7]. In this

analysis, the SNPs were mapped to genes using the same mapping as used for GWANN.

Five of these genes (*APOE* locus – *APOE, APOC1, TOMM40, BCAM* and *EXOC3L2*)

overlapped with the findings of GWANN.

When compared with other GWAS on familial history of AD, AD diagnosis, and AD-related

traits listed in the GWAS catalogue[3], there was an overlap of 26 genes with the GWANN

hits. Twelve of these have been previously associated with AD (*ANK3, APH1B, GLIS3,*

EPHA1-AS1/EPHA1, WWOX in addition to seven genes in the *APOE* region). Seven others

are listed in the GWAS catalogue as suggestive associations (*P value<1x10^{-5}*) with AD

(*EXOC4, NRXN1, NRXN3, PAX5, CADM2, LUZP2* and *RBMS3*). *DCC*, *CADM2*,

ARHGAP15 and PITPNM2 were identified in a recent analysis on pleiotropic predisposition

to AD and educational attainment[13], and *EFNA5* and *LRP1B* as suggestive associations.

DAB1 has previously been associated with psychosis in AD[14], and *MACROD2* with

neurofibrillary tangles[15].

To further understand the 69 GWANN hits that have not previously been identified in a

GWAS on AD or AD-related traits, we obtained information about them from the Agora AD

knowledge portal, which contains information about AD associated genes, collected by the

National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease

(AMP-AD) consortium as well as other research teams

(https://agora.adknowledgeportal.org). *BDNF* and *ROBO1* have been nominated as potential

targets for AD. Among the other novel genes identified by our method, *RNF182* and

SAMD4A have been reported to be significantly associated with Braak stage (neurofibrillary

tangles) and CERAD (measure of neuritic plaques); and *CPNE5, SAMD4A, ATP1B3, MAGI2*

and *ARSG* associated with COGDX (clinical consensus diagnosis of cognitive status at time

of death) (Table 2). Furthermore, from this set of 69 novel genes, 39 genes (Supplementary

Figure 1) have associations in the GWAS catalogue with at least one disorder under the

category of "nervous system disease" (EFO:0000618), comprising non-neoplastic or

neoplastic disorders that affect the brain, spinal cord, or peripheral nerves.

2.2 Enriched protein-protein interaction (PPI) network of

GWANN hits

The PPI network of the 95 associated genes identified post meta-analysis was significantly

enriched (Figure 4a). For the 95 possible proteins, the expected number of connections in

their PPI network by chance would be 23. However, the network of the GWANN hits show

72 connections, thereby being significantly enriched (*P value=$3.33x10^{-16}$*). On retaining only

the 69 genes that have not been identified in previous GWAS on AD or AD-related traits, the

PPI network was significantly enriched when the STRING interaction score was set at "low

confidence (0.15)" (*P value= $3.13x10^{-12}$*), but not enriched for higher thresholds of interaction

score (*P value=0.172*). There were 93 indirect connections (simple paths) between the novel

genes in the PPI network shown in Figure 4a, and 66 of these connections had a known AD

gene as an intermediate node. The green dotted lines in Figure 4b shows the indirect

connections. The loss of interactions after removing the known genes from the network

resulted in the drop in significance.

2.3 Enrichment of GWANN hits using transcriptomic data from AD post mortem brains

Using the results of a recent large meta-analysis of AD brain transcriptomic data by Patel et

al.[16], we verified whether the results of GWANN show significant enrichment in the set of

differentially expressed genes (DEGs) in the cerebellum, frontal lobe, parietal lobe, and

temporal lobe. The authors reported results for DEGs in different groups of patients,

denoting these as S_1=AD (patients with AD) and S_2=non-AD (i.e., patients with mental

disorders different from AD). We ran our analysis for four different sets of DEGs, (i) S_1, (ii)

S_2, (iii) S_1 - S_2 (patients with only AD and no other mental disorder), and (iv) $S_1 \cap S_2$ (patients

with any mental disorder). For each set, the DEGs in the cerebellum (*P value=1.37x10^{-3},

1.04x10^{-3}, 5.49x10^{-3}, 4.13x10^{-3}) and parietal lobe (*8.77x10^{-7}, 7.31x10^{-11}, 5.82x10^{-4}, 4.67x10^{-}

^{6}), and for sets i, ii and iii, the frontal lobe (6.38x10^{-3}, 6.46x10^{-5}, 1.10x10^{-2}) were enriched at a

significance level of 1.25x10^{-2} (*=.05/4*). For the temporal lobe, there were no DEGs reported

by the authors for set iv, and there was no enrichment in sets i, ii or iii (Table 3).

Another study by Patel et al. compared gene expression between controls, asymptomatic

AD cases, and AD cases (GSE118553)[17]. They reported DEGs in the cerebellum, entorhinal

cortex, frontal cortex, and temporal cortex, for three different conditions — (i) AD vs controls,

(ii) asymptomatic AD vs AD, and (iii) asymptomatic AD vs controls. DEGs in the entorhinal

cortex for AD vs controls, and asymptomatic AD vs AD (*P value= 3.11x10^{-5}, 9.39x10^{-5}*), and

DEGs for AD vs controls in the temporal cortex (*1.49x10^{-3}*), showed enrichment with the

GWANN summary statistics, at a significance level of 1.25x10^{-2} (*=.05/4*). In the case of

asymptomatic AD vs controls, none of the brain regions showed enrichment. Supplementary

Figures 2 and 3, respectively, contain the cumulative distribution plots used in the

enrichment of each dataset.

Furthermore, a total of 69 of the 95 associated genes (72.6%) were significantly enriched

with eQTLs in brain regions, and 51 genes showed differential RNA expression in post-

mortem AD brains (https://agora.adknowledgeportal.org) (Supplementary Table 4).

161 2.4 Enriched biological pathways, GO terms, diseases, and

162   tissues, using GWANN summary statistics and hit genes

The enriched pathways include statin inhibition of cholesterol production ($FDR=3.69x10^{-4}$);

regulation of commissural axon pathfinding by *SLIT* and *ROBO* ($3.69x10^{-3}$); *NTRK2*

signalling through *RAS* and *CDK5* ($5.41x10^{-3}$, $6.03x10^{-3}$); *RUNX1* regulation of transcription

of genes involved in BCR signalling ($6.32x10^{-3}$); disruption of postsynaptic signalling by copy

number variations (CNV) ($8.38x10^{-3}$); and Reelin signalling ($8.99x10^{-3}$). A complete list of

pathways enriched in the gene set enrichment analysis (GSEA) for maternal history, paternal

history and parental meta-analysis can be found in Supplementary Table 5.

In the over-representation analysis (ORA) (Figure 5a) using gene ontology (GO) terms, 56%

(Figure 5b) of the terms were related with the cellular response to nerve growth factor

stimulus (GO:1990090, corrected *P value=2.54x10^{-4}*). Other significant terms included Rho

protein signal transduction (GO:0035023, $3.35x10^{-3}$); neuron recognition (GO:0008038,

$2.19x10^{-2}$); amyloid-beta metabolic process (GO:0050435, $1.52x10^{-2}$); cellular component of

the Schaffer collateral - CA1 synapse (GO:0098685, $1.47x10^{-2}$); Golgi to plasma membrane

transport (GO:0006893, $5.35x10^{-3}$); and ephrin receptor signalling pathway (GO:0048013,

$2.73x10^{-3}$). The results for GO enrichment of maternal and paternal histories can be found in

Supplementary Figure 4 and Supplementary Table 7.

To further ascertain possible disease associations, we also calculated enrichment in

DisGeNET (Table 4, Figure 5c), obtaining significance in multiple disorders including AD

($2.42x10^{-5}$), schizophrenia ($1.38x10^{-6}$), autistic disorder ($6.67x10^{-7}$), bipolar disorder

($3.54x10^{-4}$) and major depressive disorder ($4.49x10^{-3}$). *APOE, ANK3, BDNF* and *NTRK2*

were common to all five disorders. Among the novel GWANN genes (those not detected in a

previous GWAS on AD or AD-related traits), there was an overlap of (i) seven genes

between AD and schizphrenia (*UBE3A, BDNF, NTRK2, SAMD4A, SERPINI1, CTNNA3,*

FLNB); (ii) six between AD and bipolar disorder (*BDNF, NFIA, ASIC2, NTRK2, BCR,*

SORCS2); (iii) five between AD and autistic disorder (*UBE3A, BDNF, ASIC2, NTRK2,*

CTNNA3); and (iv) six between AD and depressive disorder (*BDNF, ASIC2, ARHGAP24,*

NTRK2, BCR, CTNNA3). Supplementary Table 6 contains the list of GWANN genes

overlapping with all the enriched DisGeNET disorders. The GSEA also resulted in

enrichment of the pathways for Alzheimer's disease ($2.98x10^{-3}$) and amyotrophic lateral

sclerosis ($3.76x10^{-4}$), amongst all KEGG pathways.

The most enriched tissue groups were the brain (*P value*=$1.16x10^{-15}$), blood vessel ($1x10^{-13}$)

and nerve ($5.98x10^{-9}$). Figure 5d shows the enriched tissues in the GTEx v8 54 tissue types.

198 2.5 Potential of novel targets for AD drug discovery

Seventeen novel hits were reported as tractable targets for drug discovery (Supplementary

Table 8). *NTRK2, FSHR, BCR, PDE1C* and *EPHA6*, are five novel GWANN hits that have

known approved drugs (Table 4). Among these, *BCR* has 2 drugs — nilotinib and dasatinib

— associated with it, one of which has undergone, and the other is currently undergoing

clinical trials for AD. From the list of enriched pathways, *NTRK2* signalling plays an important

role in synaptic transmission and neuronal development (R-HSA-9032845 and R-HSA-

9026519) and may be a potential therapeutic target for AD. *DCC*, another GWANN hit that

was also recently associated with pleiotropic predisposition to Alzheimer's disease and

educational attainment[13], is not currently associated with any approved drug but received the

highest tractability probability of 98.47%. Given its importance in axon guidance (enriched

pathway R-HSA-428542), it could potentially be another therapeutic target to explore.

3 Discussion

We developed GWANN and applied it to identify genes associated with maternal and paternal histories of AD using data from the UKB, followed by a parental meta-analysis. In doing so, we were able to identify 26 known AD genes, when compared with previous GWAS on AD or AD-related traits, two AD target nominations, and 67 novel genes. The post-hoc enrichment analyses showed enriched biological and disease pathways relevant to AD and neurodegeneration, and other neuropsychiatric diseases. Several GWANN hits were also identified as drug targets.

3.1 GWANN identifies hits associated with AD diagnosis

Of the genes that overlap between GWANN's discovery and discovery from earlier GWAS, most of them have also been identified previously using familial history data in the UKB. However, GWANN also identified previously associated or suggestively associated genes from GWAS performed on cohorts of diagnosed AD patients that have not been identified in the UKB. *GLIS3* was previously identified in a GWAS performed on cerebrospinal fluid tau levels[18]; *WWOX* was previously identified in the IGAP data in an analysis that did not include UKB[19]. *IMMP2L*, although not identified in a previous GWAS, was previously identified in an analysis on CNVs associated with AD[20]. Among the suggestive associations, other than the genes possibly linked to AD diagnosis, *EFNA5* was suggestively associated with psychosis in AD[14], and *MACROD2* with neurofibrillary tangles[15]. *ANK3*, a novel discovery in the GWAS conducted by Bellenguez et al. on the European Alzheimer's Disease Biobank (EADB)[21], was a GWANN hit. The ability of GWANN to identify these genes from the UKB data suggests the presence of subtle patterns in the data that were possibly missed by the traditional linear models but identified by our method.

3.2 Role of hit genes and enriched biological pathways in neurodegeneration and AD

The enriched pathways of the novel hits and known suggestive hits play important roles in the pathogenesis of AD. For example, axon guidance molecules such as netrin-1 play an important role in the regulation of Aβ levels and Reelin levels[22]. Two enriched pathways, R-HSA-428542 and R-HSA-8866376 are branched under the axon guidance pathway. *DCC,* a GWANN hit, is one of the main receptors of netrin-1 and an integral component of the enriched pathway R-HSA-428542. Through (i) its interaction with *ROBO1* (GWANN hit and AD target nomination) in the presence of *SLIT*, plays an important role in controlling commissural axon growth; and (ii) its interaction with *APP,* mediates axon guidance by enhancing intracellular signalling, and may have a role in the negative regulation of Aβ formation[23]. Furthermore, the phosphorylation of *DAB1*, another GWANN hit, plays a role in Reelin signalling (R-HSA-8866376). The loss of Reelin function in humans has previously been associated with AD[24].

Another GWANN hit with previous suggestive association to AD, *PAX5*, is a transcription co-factor along with the *RUNX1* complex that plays an important role in BCR signalling and B cell development (enriched pathway R-HSA-8939245). The role of B cells in the pathogenesis of central nervous system diseases is well established, and B cell depleting therapies have shown success in patients with disorders such as multiple sclerosis[25]. A recent study in mice has also suggested the involvement of B cells in neurodegenerative diseases like AD by causing immunoglobulin deposits around Aβ plaques[26].

AD is characterised by synaptic failure[2], and disruption of postsynaptic signalling by CNVs (WP4875) was among the enriched pathways in the GSEA. Two GWANN hits, *NRXN1* and *NRXN3,* belong to the neurexin family of proteins and contribute significantly to

synaptogenesis[27]. The disruption of the functioning of these genes due to CNVs affect

synapse formation and neurodevelopment[27]. They have also previously been associated

with autism[28] and schizophrenia[29]. Recent studies suggest the intersection between the

aetiologies of AD and schizophrenia[30,31]. Another integral component of synaptic

transmission is controlled by neurotrophins like *BDNF* (GWANN hit and nominated AD

target), which play an important part in the survival, differentiation, and plasticity of neurons.

Low levels of *BDNF* mRNA in patients with AD and mild cognitive impairment is an

experimentally reproduced finding, and BDNF treatments in rodent and primate models of

AD have shown success previously[2]. *NTRK2* (or *TRKB*), a novel GWANN hit, is the main

receptor that *BDNF* binds to; *NTRK2* signalling plays a key role in neuronal development

and possibly affects hippocampal long-term potentiation (R-HSA-9620244)[2] through *CDK5*

catalytic activity (R-HSA-9032845), two pathways that were also enriched in the GSEA.

3.3 Repurposing known drugs of novel hits for AD

A large proportion of the known drugs associated with the novel GWANN hits belong to a

broader group of drugs known as tyrosine kinase inhibitors (TKI). Drugs like nilotinib and

dasatinib, among other TKIs, are being tested to be repurposed for AD due to their ability to

reduce tau hyperphosphorylation and reverse Aβ-induced synaptic dysfunction and synapse

loss in mouse models of AD-related pathology[32]. A previous study using mouse models also

identified the effect of TKIs in reducing Aβ levels and astrocyte and dendritic cell number

after treatment with nilotinib and bosutinib, two drugs associated with the novel GWANN hit

NTRK2. Other than TKIs, dipyridamole, a drug associated with the novel hit *PDE1C*, was

previously shown to prevent Aβ-induced microglial inflammation, thereby making it a

possible therapeutic intervention for AD[33]. Pentoxifylline, a methylxanthine associated with

PDE1C, has been suggested to improve cognitive function in patients with vascular

dementia[34], reduce the odds of occurrence of Parkinson's disease[35], and reduce Aβ levels[35].

This further supports the quality of the novel GWANN hits and (i) suggests the possibility of

repurposing the existing drugs for AD, and (ii) provides evidence that several of these drugs

are already being explored for the treatment of AD.

288   3.4 Limitations and considerations

Some AD hits such as *CLU*, *BIN1* and *CR1* were not identified by GWANN as genes that

reached the genome wide significance level. However, when we observe the neighbourhood

of these genes (Supplementary File 3, Supplementary Figure 5), we see that *BIN1* crossed

the nominal significance threshold *(P value = 3.2x10^{-6})*; the *CR1/CR2* locus was close to

nominal significance (*4.39x10^{-5}*); and *PBK*, a gene in LD ($r^2 \geq$ 0.25) with *CLU*, also had a P

value close to nominal significance (*6.25x10^{-5}*). Additionally, *GPR137C*, a gene in LD ($r^2 \geq$

0.8) with *FERMT2*, a hit identified previously in the UKB[7], and in the analysis by Bellenguez

et al.[21], was a GWANN hit (Supplementary File 3). To further explore this, we compared the

distribution of minor allele frequencies (MAFs) of significant SNPs in previous GWAS, and

SNPs in gene windows identified as significant by GWANN. The significant SNPs in the

genes not identified by GWANN had a different distribution (higher MAFs) as compared to

the known and novel genes identified by GWANN (Supplementary Figure 6, Supplementary

File 4), thereby suggesting GWANN to be a complementary method alongside existing

GWAS methods. Furthermore, some of the lead SNPs associated with the genes missed by

GWAS, were not analysed by GWANN because of limiting the flanking region around genes

to 2500 bp, due to computational feasibility. Hence, the difference in sample sizes, cohorts,

and SNPs used by GWANN, along with the difference in analysis model, as compared to

previous GWAS could be the factors contributing to the inability of these loci to reach

genome wide significance in this analysis. In future analyses, we plan to test the method

using larger sample sizes (larger ratio of controls:cases, instead of a 1:1 ratio), and to modify

the method to accommodate larger genomic windows. Given that the method involves

training a large number of NNs, we acknowledge the fact that it requires a fairly large

amount of computational time and resources. However, we believe that with the rapidly

advancing field of ML and AI, it is possible to further optimise this method to achieve a speed

up in computational time and reduction in resource usage. For example, the method of

"knowledge distillation" uses the concept of a larger teacher NN teaching a much smaller

student NN to learn the same task, which allows a significant speed up in time[36]. Secondly,

NNs are more difficult to interpret as compared to traditional linear models, thereby

rendering them as "black boxes". In this work we explored the gradients of the NNs to

identify the SNPs that were most important in driving the prediction, but more methods to

increase their interpretability and identify interactive effects would be beneficial in further

understanding the hits identified, and those missed by GWANN. Finally, we acknowledge the

fact that the discovery in this work warrants replication in different cohorts having diagnosis

of AD. Our method can potentially be extended to other data sources, as well as be applied

to other diseases or groups of diseases to understand the common associations, if any,

between them.

326   3.5 Conclusion

We applied our method to family history of AD using data from the UKB and introduced a

new method to complement the success of existing GWAS methods. GWANN identified

novel genes associated with family history of AD, which led to the enrichment of new

pathways such as *NTRK2* signalling through *CDK5*, and identification of possible drugs

associated with novel genes that are currently being or could be repurposed for AD. This

holds the potential to augment the effort of existing methods in understanding the

pathogenesis of AD and other diseases.

4 Methods and Materials

4.1 Population

We utilised data from the UK Biobank (UKB) (http://www.ukbiobank.ac.uk). The data comprises health, cognitive and genetic data collected from ~500,000 individuals aged between 37 and 73 years from the United Kingdom at the study baseline (2006–2010)[12,37]. We used imputed SNP genotype data as input to GWANN. UKB genotyping was conducted by Affymetrix using a BiLEVE Axiom array for 49,950 participants and on a further updated using an Affymetrix Axiom array for the remaining 438,427 individuals in this study, based on the first array (95% marker content shared). The released genotyped data contained 805,426 markers on 488,377 individuals. Information on the genotyping process is available on the UKB website (http://www.ukbiobank.ac.uk/scientists-3/genetic-data)[37]. Genotype imputation was performed combining the UK 10K haplotype and Haplotype Reference Consortium (HRC) as reference panels[38]. A number of individuals (*n=856*) either with inconsistencies between their genetic predicted and reported sex, or abnormal number of sex-chromosomes were removed. In addition, 968 outliers were identified based on heterozygosity and missingness, and removed. The dataset was further limited to only individuals of "White British" descent resulting in 409,703 remaining individuals. A genetic relationship matrix along with genome-wide complex trait analysis was used to identify 131,818 individuals with relatives within the dataset, using a relationship threshold of 0.025. Only one person from each pair of related individuals was retained. Only biallelic SNPs with MAF > 1% and imputation quality info score > 0.8 were retained for the analysis, and all indels and multi-allelic SNPs were dropped.

357 4.2 Definition of cases and controls

The case groups consisted of individuals with maternal and paternal histories of AD, some of

whom also had AD diagnosis. Individuals with diagnosed AD but no familial history of AD,

and those with other neurological disorders[39] were removed from the control groups.

Supplementary Table 9 contains a list of all the neurological disorders along with the UKB

fields used to determine the presence of the disorders. Those with both maternal and

paternal histories were dropped to avoid any overlap between the two datasets. We divided

the entire range of ages into three groups (age-group1: 38-52, age-group2: 53-61, age-

group3: 62-73 years), and paired them with the two possibilities of the individuals' sex (male

and female) to obtain six broad groups — (age-group1, male), (age-group1, female) etc. To

deal with the problem of imbalanced classes which affects the training of machine learning

algorithms, we opted to randomly downsample the controls, while balancing for the six

groups, to match the number of cases and obtain a 1:1 ratio. The sets of individuals in the

datasets for paternal history and maternal history analyses were not overlapping. After these

steps, maternal history had 26,133 cases and controls, and paternal history had 12,680

cases and controls.

373 4.3 Neural network model

GWANN follows an architecture with 2 branches that later merge into a single trunk (Figure

1). One of the branches reads contiguous SNPs within a genomic region involving each

gene, while the other reads the covariates. The common trunk combines this information to

predict family history of AD. Each sample consists of SNPs and covariates for a group of 10

individuals, with all 10 being either cases (people with family history of AD) or controls. The

NN was trained on predicting whether the sample is formed by cases or controls. The

rationale behind using convolutional layers in our architecture (Figure 1) was to implement

"group training", which allows the NNs of GWANN to consider the group of 10 cases or

controls as a single sample, enabling them to identify similar patterns across the individuals

in the group. Before passing the output of this section to the densely connected section of

the model, they are passed through an "attention" block to focus on important features and

ignore features without much information. The final feature vector, obtained from the densely

connected portion of the NN focussing on the SNPs, is concatenated with a feature vector or

encoding generated from the covariates (bottom-left branch of NN in Figure 1) and finally

passed through the densely connected end layers of the NN to obtain the final prediction.

The covariate encodings are obtained from the penultimate layer of the bottom-left branch.

Further information about the NN architecture can be found in the Supplementary File 1.

391 4.4 Training the neural network

The NNs were trained to predict the status of maternal and paternal history of AD in two

separate analyses. Gene locations were mapped according to the Genome Reference

Consortium Human Build 37 (GRCh37/hg19). The dataset for each phenotype was split into

case-control balanced training and testing sets. For maternal history, this resulted in a

training set of 44,426 and a testing set of 7,840; paternal history was split into a training set

of 21,556 and a testing set of 3,804. In order to implement "group training", we separately

upsampled the individuals in the training and testing sets by 10 and randomly grouped them

into groups of 10. We ensured no overlap of individuals between the training and testing

sets. All missing SNP values were replaced with -1 and all variables were min-max scaled

prior to training. To optimise the training process, (i) we pre-trained the covariate branch

(bottom-left branch in Figure 1); and (ii) saved and reused the encodings from the

penultimate layer, instead of passing the covariates through the pre-trained branch during

each training to obtain the same encodings.

For every gene, SNPs within the gene and in the 2500 bp flanking region (upstream and

downstream of the gene) were considered. Since NNs are computationally more intensive

than linear models, we set the limit to 2500 bp as a trade-off between increased

computational time and including downstream and upstream SNPs in the analysis. This also

minimised the chances of overlap between genes which are very close to each other. We

divided every gene into windows of maximum 50 SNPs and the final analysis was done on

all windows of all genes. A different NN was trained for each window per gene in the entire

genome. This resulted in having to train a total of 73,310 models for maternal history and

73,299 models for paternal history. The NN models were built and trained using PyTorch[40], a

Python library built and optimised for machine learning and deep learning.

4.5 Identifying significantly associated genes

417 A null distribution of accuracies, A_{null}, was obtained from a set of NNs trained on the same

418 covariate encodings along with simulated SNP data generated using the "dummy" command

419 of PLINK 2.0[41,42]. The P value of window i was obtained as $1 - CDF_{null}(a_i)$, where CDF_{null} is

420 the cumulative distribution function of the distribution fit to A_{null}, and a_i is the NN accuracy for

421 window i.

4.6 Meta-analysis for parental histories of AD

After conducting separate analyses for maternal and paternal histories of AD, for each

phenotype, we assigned a gene-level P value as the most significant P value amongst all

windows for that gene. Following this, we used METAL[43] to perform a gene-level meta-

analysis of the parental histories of AD (maternal and paternal). Since NNs do not produce

beta values or standard errors, the "sample size weighted" method was used and the

"weight" parameter for maternal and paternal histories were set as 7,840 and 3,804

respectively, the number of samples in the testing set for each analysis. After the meta-

analysis, LDLink[44] was used to find the LD between SNPs using the "British in England and

Scotland" population. A pair of genes were reported to be in LD at a given threshold if any

SNPs mapped to these genes were in LD with each other.

4.7 Enrichment and post-hoc analyses

We used information from the Agora AD knowledge portal

(https://agora.adknowledgeportal.org) to identify genes that have (i) significant eQTLs in the

brain; (ii) change in RNA expression in post-mortem AD brains; (iii) AD target nominations;

and (iv) association with AD cognitive phenotypes (Braak stage, CERAD and COGDX).

STRING V11.5[45] was used to perform PPI analysis of the genes that were significantly

associated after the parental meta-analysis. Pathway enrichment was performed using

GSEA[46]. This enrichment was performed using the gene-level statistics for the parental

meta-analysis for all analysed genes. The enrichment was performed for KEGG, Wiki and

Reactome pathways present in the canonical pathways of MSigDB v7.5.1[47]. Using the same

method, we also performed an enrichment analysis of DEG sets for different AD-related

conditions, in different brain regions from two studies — meta-analysis of AD brain

transcriptomic data[16] and GSE118553[17] —, with the exception of multiple testing corrections.

Instead of using an empirical FDR, for each condition reported in the study, we applied a

Bonferroni correction for the number of DEG sets (different brain regions) that were

analysed. In addition to the GSEA, we performed a GO ORA of the GWANN hits using

ClueGO v2.5.8[48] and a disease enrichment analysis with DisGeNET[49]. FUMA[50] was used to

identify tissues enriched using the GWANN genes with P value$<1 \times 10^{-5}$. Finally, we used

TargetDB[51] to get a picture of the tractability or suitability of the novel GWANN hits for

intervention by modalities such as small molecules or antibodies. The details and

parameters of implementation for the different analyses can be found in the Supplementary

File 1.

Data Availability

GWANN summary statistics and the summaries for all post-hoc analyses are available in the

Supplementary Tables (see Supplementary File 1 for table descriptions).

STRING analysis of the PPI network of GWANN hits can be found here: https://version-11-

5.string-db.org/cgi/network?networkId=bAnWnXnBtjR4

Data on brain eQTLS, RNA change in the brain, and AD pathology measures were obtained

from the Agora AD knowledge portal (https://agora.adknowledgeportal.org), site version

3.0.0, and data version syn13363290-v40.

Code Availability

Code used in the analysis will be made available upon request.

Acknowledgments

We thank the UK Biobank participants and the UK Biobank team for their work in collecting,

processing, and disseminating these data for analysis. This research was conducted using

the UK Biobank Resource under the approved project 15181. The results published here are

in part based on data obtained from Agora (https://agora.adknowledgeportal.org), a platform

initially developed by the NIA-funded AMP-AD consortium that shares evidence in support of

AD target discovery.

Funding: This work was supported by the Centre for Artificial Intelligence in Precision

Medicines (CAIPM); Johnson and Johnson; the John Fell Foundation [grant ID 0010659];

and the Virtual Brain Cloud from European commission [grant number H2020-SC1-DTH-

2018-1]. C.A. is funded by the National Institute for Health Research (NIHR) Oxford

Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not

necessarily those of the NHS, the NIHR or the Department of Health.

Conflicts of Interest / Competing Interests

W.S. is funded by Johnson and Johnson. A.N.H. received funding from Johnson and Johnson, GlaxoSmithKline, and Ono Pharma.

Author Contributions

U.G.: Conceptualisation, Methodology, Software, Formal analysis, Visualization, Writing - Original Draft. **W.S.**: Conceptualisation, Methodology, Formal analysis, Writing - Original Draft. **L.W.**: Methodology, Investigation, Writing - Original Draft. **M.F.**: Formal analysis, Visualisation, Writing - Original Draft. **D.N.**: Investigation, Writing - Review & Editing. **B.S.U.**: Formal analysis, Writing - Review & Editing. **Q.L.**: Software. **L.S., C.A., A.A., M.A., H.C.**: Writing - Review & Editing. **C.V.D.**: Supervision, Writing - Review & Editing. **A.N.H.**: Conceptualisation, Methodology, Supervision, Writing - Review & Editing.

References

1. Serge Gauthier, Pedro Rosa-Neto, José A. Morais, & Claire Webster. *World Alzheimer*
Report 2021: Journey through the diagnosis of dementia. (2021).

2. Querfurth, H. W. & LaFerla, F. M. Alzheimer's disease. *N. Engl. J. Med.* **362**, 329–344
(2010).

3. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–
D1012 (2019).

4. Manolio, T. A. *et al.* Finding the missing heritability of complex diseases. *Nature* **461**,
747–753 (2009).

5. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS
discovery. *Am. J. Hum. Genet.* **90**, 7–24 (2012).

6. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
Set Analysis of GWAS Data. *PLOS Comput. Biol.* **11**, e1004219 (2015).

7. Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl. Psychiatry* **8**,
99 (2018).

8. Alzheimer Disease Genetics Consortium (ADGC), *et al.* Genetic meta-analysis of
diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity
and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).

9. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
identifies new risk loci for Alzheimer's disease. *Nat. Genet.* **53**, 1276–1282 (2021).

10. Rusk, N. Deep learning. *Nat. Methods* **13**, 35–35 (2016).

11. van Hilten, A. *et al.* GenNet framework: interpretable deep learning for predicting
phenotypes from genetic data. *Commun. Biol.* **4**, 1–9 (2021).

12. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a

Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779

(2015).

13. Kulminski, A. M., Loiko, E., Loika, Y. & Culminskaya, I. Pleiotropic predisposition to

Alzheimer's disease and educational attainment: insights from the summary statistics

analysis. *GeroScience* **44**, 265–280 (2022).

14. DeMichele-Sweet, M. A. A. *et al.* Genome-wide association identifies the first risk loci for

psychosis in Alzheimer disease. *Mol. Psychiatry* **26**, 5797–5811 (2021).

15. Dumitrescu, L. *et al.* Sex differences in the genetic predictors of Alzheimer's pathology.

Brain J. Neurol. **142**, 2581–2589 (2019).

16. Patel, H., Dobson, R. J. B. & Newhouse, S. J. A Meta-Analysis of Alzheimer's Disease

Brain Transcriptomic Data. *J. Alzheimers Dis. JAD* **68**, 1635–1656 (2019).

17. Patel, H. *et al.* Transcriptomic analysis of probable asymptomatic and symptomatic

alzheimer brains. *Brain. Behav. Immun.* **80**, 644–656 (2019).

18. Cruchaga, C. *et al.* GWAS of cerebrospinal fluid tau levels identifies risk variants for

Alzheimer's disease. *Neuron* **78**, 256–268 (2013).

19. Lambert, J. C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility

loci for Alzheimer's disease. *Nat. Genet.* **45**, 1452–1458 (2013).

20. Swaminathan, S. *et al.* Analysis of Copy Number Variation in Alzheimer's Disease: the

NIA-LOAD/NCRAD Family Study. *Curr. Alzheimer Res.* **9**, 801–814 (2012).

21. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and

related dementias. *Nat. Genet.* 1–25 (2022) doi:10.1038/s41588-022-01024-z.

22. Zhang, L. *et al.* Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer's

Disease. *Mol. Neurobiol.* **58**, 3290–3307 (2021).

23. Rama, N. *et al.* Amyloid precursor protein regulates netrin-1-mediated commissural axon

outgrowth. *J. Biol. Chem.* **287**, 30014–30023 (2012).

24. Sentürk, A., Pfennig, S., Weiss, A., Burk, K. & Acker-Palmer, A. Ephrin Bs are essential

components of the Reelin pathway to regulate neuronal migration. *Nature* **472**, 356–360

(2011).

25. Sabatino, J. J., Pröbstel, A.-K. & Zamvil, S. S. B cells in autoimmune and

neurodegenerative central nervous system diseases. *Nat. Rev. Neurosci.* **20**, 728–745

(2019).

26. Kim, K. *et al.* Therapeutic B-cell depletion reverses progression of Alzheimer's disease.

Nat. Commun. **12**, 2185 (2021).

27. Dean, C. & Dresbach, T. Neuroligins and neurexins: linking cell adhesion, synapse

formation and cognitive function. *Trends Neurosci.* **29**, 21–29 (2006).

28. Glessner, J. T. *et al.* Autism genome-wide copy number variation reveals ubiquitin and

neuronal genes. *Nature* **459**, 569–573 (2009).

29. Walsh, T. *et al.* Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental

Pathways in Schizophrenia. *Science* **320**, 539–543 (2008).

30. Kochunov, P. *et al.* A White Matter Connection of Schizophrenia and Alzheimer's

Disease. *Schizophr. Bull.* **47**, 197–206 (2020).

31. Douaud, G. *et al.* A common brain network links development, aging, and vulnerability to

disease. *Proc. Natl. Acad. Sci.* **111**, 17648–17653 (2014).

32. Cohen, P., Cross, D. & Jänne, P. A. Kinase drug discovery 20 years after imatinib:

progress and future directions. *Nat. Rev. Drug Discov.* **20**, 551–569 (2021).

33. Paris, D. *et al.* Inhibition of Alzheimer's β-Amyloid Induced Vasoactivity and

Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. *Exp. Neurol.*

157, 211–221 (1999).

34. Sha, M. C. & Callahan, C. M. The Efficacy of Pentoxifylline in the Treatment of Vascular

Dementia: A Systematic Review. *Alzheimer Dis. Assoc. Disord.* **17**, 46–54 (2003).

35. Janitschke, D. *et al.* Methylxanthines and Neurodegenerative Diseases: An Update.

Nutrients **13**, 803 (2021).

36. Hinton, G., Vinyals, O. & Dean, J. Distilling the Knowledge in a Neural Network. in *NIPS*

Deep Learning and Representation Learning Workshop (2015).

37. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

38. Huang, J. *et al.* Improved imputation of low-frequency and rare variants using the UK10K

haplotype reference panel. *Nat. Commun.* **6**, 8111 (2015).

39. Newby, D. *et al.* The relationship between isolated hypertension with brain volumes in

UK Biobank. *Brain Behav.* **12**, e2525 (2022).

40. Paszke, A. *et al.* PyTorch: an imperative style, high-performance deep learning library. in

Proceedings of the 33rd International Conference on Neural Information Processing

Systems 8026–8037 (Curran Associates Inc., 2019).

41. Purcell, Shaun & Chang, Christopher. PLINK 2.0.

42. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *GigaScience* **4**, s13742-015-0047–8 (2015).

43. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

44. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring

population-specific haplotype structure and linking correlated alleles of possible

functional variants. *Bioinformatics* **31**, 3555–3557 (2015).

45. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased

coverage, supporting functional discovery in genome-wide experimental datasets.

Nucleic Acids Res. **47**, D607–D613 (2019).

46. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for

interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550

(2005).

47. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**,

1739–1740 (2011).

48. Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene

ontology and pathway annotation networks. *Bioinforma. Oxf. Engl.* **25**, 1091–1093

(2009).

49. Piñero, J. *et al.* The DisGeNET knowledge platform for disease genomics: 2019 update.

Nucleic Acids Res. **48**, D845–D855 (2020).

50. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and

annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).

51. De Cesco, S., Davis, J. B. & Brennan, P. E. TargetDB: A target information aggregation

tool and tractability predictor. *PloS One* **15**, e0232644 (2020).

 # Figure captions

Figure 1. NN architecture used in the GWANN method. The top-left branch generates a

1D encoding from the SNPs input (green), while the bottom-left branch does so for the

covariate input (red). The right trunk merges the encodings of both branches to output

whether the input belongs to cases (blue output) or controls (red output).

Figure 2. Manhattan plot of the parental meta-analysis. The threshold for genome wide

significance (P value<6.82×10^{-7}) is indicated by the red dotted line. GWANN identified 21

known hits, 2 nominated AD targets and 72 novel gene hits. The black dotted line indicates

the suggestive association threshold (P value<1×10^{-5}).

Figure 3. Overlap analysis of GWANN hits, traditional GWAS hits on the GWANN

cohort, and hits in the recent GWAS on the EADB cohort[21]**.** (a) Venn diagram of 69

maternal, 29 paternal and 95 meta-analysis genes with P value<6.82×10^{-7} in each analysis.

(b) Analysis of the intersection of hit genes between the methods on the x axis and y axis.

The number of genes in the sets and intersections are specified within the brackets and the

intensity of each block (darker is more significant) represents the significance of the size of

the intersection set, given the 2 individual sets. Blocks in grey suggest an insignificant

number of genes in the intersection. The EADB set is without the *APOE* locus, and hence

the intersection with the traditional UKB GWAS (using the same data set as used for

GWANN) results in a null set.

Figure 4. PPI network of GWANN hits from STRING. Red - old hits/suggestive hits,

orange - nominated hits, blue - novel hits. The grey solid lines indicate a direct connection

between two genes and the green dotted lines indicate an indirect connection through a

known hit. In each of the networks, the node with the highest degree (most interactions) is

the bottommost node followed by decreasing degree in the anti-clockwise direction. (a) PPI

network containing the 46 (inclusive of old, nominated, and novel hits) out of the 95 hits that

had connections with each other. (b) The same network as in (a) after removing all known

hits.

Figure 5. Go term, disease, and tissue enrichment of the GWANN hits. (a) GO term over

representation analysis for GWANN meta-analysis hits using ClueGO v2.5.8. For network

visualisation purposes, GO child terms spanning more than two were grouped and collapsed

into a node (white nodes). V-shaped gene nodes correspond to either antisense, '*BDNF-AS*'

as opposed to *BDNF*; or flanking sequence regions, between '*PDCD10*' and '*SERPINI1*'. GO

node size is proportional to the number of genes enriched in the group. (b) Pie chart showing

the percentage of GWANN hits in each GO term. (c) Dotplot of the disease enrichment

analysis with DisGeNET, with gene ratio (x-axis, #input genes / #genes in disease term);

disease terms from a multitude of disease-gene databases (y-axis); false discovery rate

(FDR) for each disease enriched term; and number of genes (#genes found in the disease

term). (d) Tissue specificity plot (up and down regulated) for GTEx v8 54 tissue types using

GWANN genes with P value$<1\times10^{-5}$ in the paternal meta-analysis. Significantly enriched

tissues ($P_{bon}<0.05$) are highlighted in red.

Tables

Table 1. GWANN hit genes after the meta-analysis.

HGNC Symbol	CHR	P_{m+p}	P_m	P_p	HGNC Symbol	CHR	P_{m+p}	P_m	P_p
DAB1 [k]	1	6.50E-08	9.00E-06	2.00E-03	PITPNM2 [k]	12	7.50E-08	6.10E-10	6.00E-01
NRXN1 [k]	2	3.40E-09	4.20E-06	1.90E-04	NRXN3 [k]	14	2.80E-08	2.60E-05	2.30E-04
LRP1B [k]	2	3.40E-08	1.90E-05	4.50E-04	APH1B [k]	15	3.80E-11	4.40E-09	1.70E-03
ARHGAP15 [k]	2	7.80E-08	2.60E-05	7.60E-04	WWOX [k]	16	1.30E-10	6.90E-08	4.50E-04
RBMS3 [k]	3	9.30E-08	4.90E-04	1.40E-05	DCC [k]	18	2.10E-08	2.90E-06	2.00E-03
CADM2 [k]	3	2.30E-07	1.90E-05	3.60E-03	APOE [k]	19	9.60E-190	1.00E-65	1.80E-158
EFNA5 [k]	5	2.60E-08	1.80E-08	9.70E-02	TOMM40 [k]	19	9.60E-170	1.00E-65	2.40E-127
EPHA1-AS1 [k]	7	2.70E-07	2.20E-02	1.20E-08	APOC1 [k]	19	9.40E-153	1.00E-65	2.50E-102
EXOC4 [k]	7	6.50E-08	8.80E-07	1.60E-02	BCAM [k]	19	7.50E-75	1.00E-64	2.20E-14
GLIS3 [k]	9	4.10E-20	6.90E-08	8.40E-17	GEMIN7 [k]	19	1.60E-21	2.60E-28	4.00E-01
PAX5 [k]	9	2.80E-08	1.30E-06	5.60E-03	EXOC3L2 [k]	19	8.90E-08	3.50E-08	1.50E-01
ANK3 [k]	10	3.60E-10	2.80E-08	2.70E-03	PPP1R37 [k]	19	1.90E-08	6.90E-08	3.70E-02
LUZP2 [k]	11	1.90E-10	1.30E-06	2.70E-05	MACROD2 [k]	20	4.80E-11	5.30E-05	1.20E-08

HGNC Symbol	CHR	P_{m+p}	P_m	P_p	HGNC Symbol	CHR	P_{m+p}	P_m	P_p
FGGY	1	2.60E-10	2.20E-10	5.20E-02	VIPR2	7	2.80E-09	8.80E-04	1.90E-08
NFIA	1	5.40E-13	1.40E-14	1.20E-01	CRISPLD1	8	4.10E-07	2.80E-08	3.70E-01
PIGK	1	6.40E-08	6.90E-08	8.60E-02	EXT1	8	3.10E-08	2.00E-06	4.30E-03
FSHR	2	6.80E-10	1.40E-02	3.50E-13	PEBP4	8	4.40E-07	3.20E-02	8.30E-09
LYPD6B	2	5.80E-07	2.90E-06	4.20E-02	SGCZ	8	2.80E-08	5.90E-07	1.10E-02
MYT1L	2	1.60E-11	1.10E-08	3.20E-04	NTRK2	9	1.40E-07	2.90E-06	1.30E-02
PARD3B	2	1.90E-10	2.50E-07	1.90E-04	CTNNA3	10	1.20E-07	5.30E-05	5.50E-04
TANC1	2	2.80E-08	1.30E-06	5.60E-03	HPSE2	10	3.00E-11	1.50E-11	5.20E-02
ATP1B3	3	5.60E-09	2.70E-09	9.70E-02	WDR11-AS1	10	5.80E-07	5.90E-07	1.20E-01
ATP2C1	3	1.20E-07	5.90E-07	3.70E-02	BDNF	11	3.00E-08	6.10E-06	1.40E-03
CHCHD6	3	3.20E-07	2.00E-03	6.50E-06	CNTN5	11	3.80E-07	4.90E-04	1.00E-04
CNTN4	3	2.70E-11	2.80E-08	2.30E-04	ELP4	11	1.80E-08	2.60E-05	1.30E-04
EPHA6	3	1.90E-07	6.20E-06	8.60E-03	LRRC4C	11	4.90E-07	1.30E-05	1.10E-02
FLNB	3	6.50E-08	9.00E-06	2.00E-03	USP47	11	2.10E-08	4.40E-03	1.20E-08
IQSEC1	3	4.70E-11	4.40E-09	2.00E-03	MGAT4C	12	8.20E-09	1.10E-08	5.90E-02
ROBO1	3	2.10E-08	1.80E-08	8.60E-02	C1QTNF9	13	1.30E-07	5.60E-08	1.50E-01
SERPINI1	3	1.70E-07	7.40E-05	5.50E-04	MTUS2	13	8.90E-12	1.70E-09	1.00E-03
STAC	3	4.90E-07	2.60E-05	5.60E-03	NALCN	13	2.50E-07	7.10E-03	2.40E-07
UBE2E2	3	5.40E-08	4.20E-06	3.60E-03	SMAD9	13	1.90E-12	3.40E-16	5.40E-01
ARHGAP24	4	3.10E-08	4.40E-09	2.10E-01	GPR137C	14	4.90E-07	6.90E-08	2.90E-01
SORCS2	4	4.50E-08	7.40E-05	1.00E-04	SAMD4A	14	5.20E-08	1.80E-08	1.50E-01
ARHGEF28	5	6.60E-11	6.90E-08	2.30E-04	CORO2B	15	1.30E-08	2.50E-07	1.10E-02
COL23A1	5	2.40E-08	7.10E-03	3.50E-09	UBE3A	15	1.30E-07	1.00E-09	6.30E-01
TENM2	5	1.80E-12	6.20E-06	5.00E-09	MYH11	16	6.30E-07	2.60E-05	7.30E-03
CPNE5	6	2.60E-08	1.80E-08	9.70E-02	TMEM170A	16	1.60E-07	6.90E-08	1.50E-01

Gene	Chr				Gene	Chr			
KIF13A	6	1.60E-08	7.00E-09	1.20E-01	ARSG	17	1.90E-15	1.30E-18	2.10E-01
RNF182	6	3.00E-07	4.90E-04	7.60E-05	ASIC2	17	1.60E-08	1.80E-08	7.20E-02
BAIAP2L1	7	1.90E-07	1.10E-07	1.40E-01	BAHCC1	17	1.80E-08	2.80E-08	5.90E-02
CARD11	7	7.70E-08	1.30E-05	1.70E-03	LMAN1	18	1.60E-08	1.10E-07	2.40E-02
IMMP2L	7	1.60E-07	2.00E-04	1.30E-04	ICAM3	19	6.40E-08	6.90E-08	8.60E-02
MAGI2	7	8.90E-12	1.70E-09	1.00E-03	SNRPB2	20	2.50E-12	4.80E-14	1.50E-01
PDE1C	7	6.60E-11	6.10E-10	1.10E-02	C2CD2	21	7.70E-14	4.40E-09	3.30E-06
PTPRN2	7	5.60E-09	1.90E-05	5.10E-05	LINC00113	21	3.70E-09	7.70E-11	3.30E-01
TYW1B	7	5.90E-08	2.90E-06	5.60E-03	BCR	22	8.20E-09	1.70E-09	1.50E-01

656   P_{m+p} represents the METAL meta-analysis P value, P_m the GWANN maternal analysis P

657   value and P_p the GWANN paternal analysis P value.

658   k – Known gene, associated with AD or AD-related traits in previous GWAS

660 **Table 2. GWANN hit genes that had significant association with AD pathology**

661 **measures.**

HGNC Symbol	Brain eQTL	RNA change in brain	Braak (adj_p)	CERAD (adj_p)	COGDX (adj_p)
APOC1	**TRUE**	**TRUE**	**8.85×10^{-03}**	**3.29×10^{-02}**	5.87×10^{-02}
ARSG	**TRUE**	**TRUE**	7.55×10^{-01}	6.38×10^{-01}	**2.24×10^{-02}**
MAGI2	**TRUE**	**TRUE**	3.91×10^{-01}	5.70×10^{-01}	**3.79×10^{-02}**
PDE1C	**TRUE**	FALSE	2.35×10^{-01}	**6.99×10^{-03}**	9.28×10^{-01}
ATP1B3	**TRUE**	**TRUE**	3.62×10^{-01}	2.35×10^{-01}	**1.09×10^{-02}**
CPNE5	**TRUE**	**TRUE**	7.24×10^{-02}	2.20×10^{-01}	**3.39×10^{-02}**
NRXN3	**TRUE**	**TRUE**	6.92×10^{-01}	7.34×10^{-01}	**2.32×10^{-02}**
SAMD4A	**TRUE**	**TRUE**	**2.61×10^{-05}**	**3.11×10^{-04}**	**2.60×10^{-05}**
PITPNM2	**TRUE**	FALSE	**1.69×10^{-02}**	7.54×10^{-02}	1.60×10^{-01}
RNF182	**TRUE**	FALSE	**4.58×10^{-02}**	**1.32×10^{-03}**	1.85×10^{-01}
LYPD6B	**TRUE**	TRUE	6.58×10^{-01}	**4.41×10^{-02}**	8.45×10^{-01}

664 The pathology measures considered were Braak stage, CERAD and COGDX. All GWANN

665 hits that had significant association with at least one of these measures have been reported.

666 The data presented in this table was obtained from the Agora AD knowledge portal

667 (https://agora.adknowledgeportal.org/).

669 **Table 3**. **Enrichment of DEGs identified in two transcriptomic studies on AD brains.**

a	AD	Other brain disorders	Only AD	AD and other brain disorders
Cerebellum	1.37×10^{-3}*	1.04×10^{-3}*	5.49×10^{-3}*	4.13×10^{-3}*
Parietal lobe	8.77×10^{-7}*	7.31×10^{-11}*	5.82×10^{-4}*	4.67×10^{-6}*
Frontal lobe	6.38×10^{-3}*	6.46×10^{-5}*	1.10×10^{-2}*	2.01×10^{-2}
Temporal lobe	5.82×10^{-2}	4.06×10^{-1}	5.82×10^{-2}	-

b	AD vs control	Asymptomatic AD vs AD	Asymptomatic AD vs Controls
Cerebellum	6.11×10^{-1}	8.26×10^{-1}	1.46×10^{-1}
Entorhinal cortex	3.11×10^{-5}*	9.39×10^{-5}*	5.53×10^{-1}
Frontal cortex	4.34×10^{-2}	3.89×10^{-2}	1.55×10^{-1}
Temporal cortex	1.49×10^{-3}*	2.24×10^{-2}	5.93×10^{-2}

The enrichments were performed using the GWANN meta-analysis summary statistics. (a)

Enrichment P values of DEGs in four different brain regions for AD and other mental

disorders analysed by Patel et al.[16] (b) Enrichment P values of DEGs in four different brain

regions for the analysis between AD, asymptomatic AD and controls by Patel et al.[17]

* P value $< 1.25 \times 10^{-2}$

Table 4. Disease enrichment of the GWANN hit genes using the DisGeNET database.

Disease	FDR	GWANN hit count	Disease	FDR	GWANN hit count
Alzheimer's Disease	2.42×10^{-05}	38	Adolescent Idiopathic Scoliosis	1.05×10^{-07}	19
Schizophrenia	1.38×10^{-06}	37	Bipolar Disorder	3.54×10^{-04}	19
Mathematical Ability	6.82×10^{-14}	29	Systolic Pressure	2.01×10^{-05}	18
Obesity	2.36×10^{-03}	29	Autism Spectrum Disorders	3.54×10^{-04}	18
Body Mass Index	2.55×10^{-11}	28	Major Depressive Disorder	4.49×10^{-03}	17
Leukaemia, Myelocytic, Acute	3.70×10^{-02}	27	Impaired Cognition	4.81×10^{-02}	17
Intellectual Disability	7.02×10^{-04}	26	Abnormal Behaviour	6.18×10^{-03}	14
Autistic Disorder	6.67×10^{-07}	23	Familial (FPAH)	2.26×10^{-02}	14
Seizures	8.28×10^{-03}	23	Blood Protein Measurement	3.78×10^{-02}	14
Intelligence	1.58×10^{-09}	21	Attention Deficit Hyperactivity Disorder	9.41×10^{-03}	13
Neurodevelopmental Disorders	5.72×10^{-10}	20	Anxiety	4.30×10^{-02}	13
Global Developmental Delay	1.56×10^{-02}	20	Developmental Delay (Disorder)	1.74×10^{-03}	12
Body Height	2.26×10^{-02}	20	Alzheimer Disease, Late Onset	3.28×10^{-04}	11
Smoking	2.94×10^{-11}	19	Mental Disorders	4.24×10^{-02}	11
Scoliosis, Isolated, Susceptibility To, 3	1.43×10^{-08}	19	Dementia	4.93×10^{-02}	11

681 Gene sets belonging to different diseases and traits that were significantly enriched after

682 applying a false discovery rate (FDR) correction. Column "GWANN hit count" indicates the

683 number of GWANN hit genes that were part of the disease gene sets.

 Table 5. Novel GWANN hits with known associated drugs and the main category of

 diseases they are used for.

HGNC symbol	Drug Name	Type	Associated disease
BCR	Bosutinib	Small molecule	Cancer
	Dasatinib	Small molecule	Cancer
	Imatinib	Small molecule	Cancer
	Imatinib mesylate	Small molecule	Cancer
	Nilotinib	Small molecule	Cancer
	Nilotinib hydrochloride monohydrate	Small molecule	Cancer
	Ponatinib	Small molecule	Cancer
	Ponatinib hydrochloride	Small molecule	Cancer
	Radotinib	Small molecule	Cancer
EPHA6	Vandetanib	Small molecule	Cancer
FSHR	Corifollitropin alfa	Protein	Infertility
			Obesity
			Hypogonadotropic hypogonadism
	Follitropin alfa	Protein	Infertility
			Polycystic ovary syndrome
	Menotropins	Protein	Infertility
			Hypogonadotropic hypogonadism
			Polycystic ovary syndrome
			Kallmann syndrome
	Urofollitropin	Unknown	Infertility
NTRK2	Altiratinib	Small molecule	Cancer
	AZD-6918	Small molecule	Cancer
	AZD-7451	Small molecule	Glioblastoma multiforme
	Cenegermin	Protein	Cancer
	Entrectinib	Small molecule	Cancer
			Neoplasm
	Larotrectinib	Small molecule	Cancer
			Neoplasm
	Larotrectinib sulfate	Small molecule	Leukaemia
	Lestaurtinib	Small molecule	Giant cell tumour
	PLX-7486	Small molecule	Neoplasm

HGNC symbol	Drug Name	Type	Associated disease
	Selitrectinib	Small molecule	Keratitis, eye disease
PDE1C	Dipyridamole	Small molecule	Stroke
			Heart disease
			Bipolar disorder
			Diabetes mellitus
			COVID-19
	Pentoxifylline	Small molecule	Diabetes mellitus
			Brain disease
			Hepatic disease

689   TargetDB was used to identify the hits with known associated drugs, and the specific list of

690   drugs and diseases were obtained from OpenTargets.